BIIB Stock Analysis: Buy, Sell, or Hold?
BIIB - Biogen Inc. Common Stock
$191.37
-13.16 (-6.43%)
▼
5d:
-0.01%
30d:
+6.0%
90d:
-2.11%
BUY
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When BIIB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called BIIB this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BIIB shows positive signals but monitor for confirmation. Market pricing in 2.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: BIIB shows positive signals but monitor for confirmation. Market pricing in 2.2% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$361.91
Based on 13.9% avg growth
INTRINSIC VALUE TODAY
$224.72
14.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BIIB is currently trading at $191.37, which is considered slightly high relative to its 30-day fair value range of $177.41 to $193.47. The stock's valuation (Forward PE: 12.3) is in line with its historical norms (11.5). At these levels, the market is pricing in 2.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BIIB is in a uptrend. Immediate support is located at $185.44, while resistance sits at $205.97. Short-term momentum is weak, with the stock down 6.4% recently.
Market Sentiment: BIIB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BIIB is in a uptrend. Immediate support is located at $185.44, while resistance sits at $205.97. Short-term momentum is weak, with the stock down 6.4% recently.
Market Sentiment: BIIB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$177.41 -
$193.47
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
67.6%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.4%)
- NEUTRAL: Near Wall St target ($217.03)
- NEUTRAL: Market pricing in 2.2% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$177.41 -
$193.47
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$185.44
Resistance Level
$205.97
Current Trend
Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.34
Wall Street Target
$217.03
(+6.1%)
Revenue Growth (YoY)
1.9%
Earnings Growth (YoY)
31.1%
Profit Margin
13.8%
Valuation Premium vs History
+2.2% premium
PE vs Historical
12.3 vs 11.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.2%
(market-implied from PE analysis)
1-Year Target
$209.03
(+2%)
2-Year Target
$213.63
(+4%)
3-Year Target
$218.33
(+7%)
3-Yr Target (if PE normalizes)
(PE: 12→12)
PE COMPRESSION
$203.45
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 23.8%)
$692.49
(+239%)
Base:
(SPY PE: 12.3, Growth: 23.8%)
$387.76
(+90%)
Bear:
(PE: 10.5, Growth: 23.8%)
$329.59
(+61%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 22.06 | Current EPS (TTM): $9.29
Bull Case
$402.13
(+97%)
Analyst growth 78.4%, PE expands to 24.3
Base Case
$365.57
(+79%)
Market implied 78.4%, PE stable at 22.1
Bear Case
$139.35
(-32%)
Severe decline -20.0%, PE contracts to 18.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 14, 2026 4:34 PM ET
Data refreshes hourly during market hours. Next update: 5:34 PM
Data refreshes hourly during market hours. Next update: 5:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIIB showing a specific setup today?
Insider Activity (6 Months)
3
Buys
3
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Nicole Murphy
BUY
3 shares
2026-02-12
Priya Singhal
SELL
2660 shares
2026-02-09
Ro Khanna
SELL
2026-02-06
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 62 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 60 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$252 | 61 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 57 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$130 | 63 BUY |
Advanced BIIB Option Strategies
Professional options setups generated by AI based on today's BIIB price and gamma walls.
